Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 31, 2024 09:00 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Closes on Financing of up to $12.4 Million

TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
December 04, 2024 09:00 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
November 14, 2024 17:30 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company’s...
November 06, 2024 09:00 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
October 25, 2024 16:10 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
October 16, 2024 09:20 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
October 15, 2024 09:00 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
October 11, 2024 09:00 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience to Participate in Upcoming October Investor Conferences

TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
September 20, 2024 09:00 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis

TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
September 10, 2024 09:00 ET | Source: Firefly Neuroscience, Inc.

Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform

TORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right